Basaglar Follow-On Insulin Booms For Eli Lilly

Lilly’s Basaglar insulin glargine hybrid is well on its way to becoming a billion-dollar blockbuster.

DollarsGraph
Rapid volume uptake in the US is pushing Eli Lilly's Basaglar follow-on insulin towards blockbuster status • Source: Shutterstock

Eli Lilly’s Basaglar follow-on version of insulin glargine was among the US-based originator’s fastest-growing brands last year, registering an 85% sales gain to US$801 million. At the current rate of rise, the diabetes drug will soon be a billion-dollar blockbuster.

The main driver of this growth was sales in the US – where Basaglar was approved through the hybrid 505(b)(2)...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business